Paper 13407-67
Prediction of kidney function decline in patients with autosomal dominant polycystic kidney disease using radiomic features extracted from the non-cystic kidney parenchyma
19 February 2025 • 5:30 PM - 7:00 PM PST | Golden State Ballroom
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disease and is responsible for 10% of patients less than 65 years of age with end-stage kidney disease. ADPKD results in gradual enlargement of total kidney volume due to cyst growth over decades prior to decline in kidney function and kidney failure. The purpose of this work was (1) to determine whether radiomic features extracted from the non-cystic kidney parenchyma in baseline magnetic resonance imaging (MRI) scans reliably predict kidney function decline to chronic kidney disease stage 3A or greater at 60-months follow-up and (2) to determine whether radiomic features at 24-month and 48-month timepoints provide additional power in predicting kidney function decline versus baseline radiomic features alone. This is the first work to investigate the utility of MRI-based radiomic features extracted from the non-cystic kidney parenchyma in ADPKD to predict kidney function decline.
Presenter
Linnea E. Kremer
The Univ. of Chicago (United States)
Dr. Linnea Ellen Kremer received her B.S. in physics from Roanoke College, her M.Sc. in bioengineering from the University of Nottingham (U.K.), and her Ph.D. in medical physics from the University of Chicago. She is currently a Postdoctoral Scholar in Dr. Arlene Chapman's lab at the University of Chicago Department of Nephrology, focusing on MRI radiomics analysis in autosomal dominant polycystic kidney disease.